Get Your Personalized Supplement StackSupplement Stack Quiz

Caffeine Citric Acid Blend

Q: Is caffeine citrate safe for preterm infants?

Yes, caffeine citrate is generally safer than aminophylline, with significantly fewer side effects in preterm infants.

Q: How should caffeine citrate be administered?

It should be given at consistent intervals, typically every 24 hours, to maintain therapeutic concentration.

Q: When can results be expected from caffeine citrate treatment?

Most benefits are observed within 1-3 days of starting treatment, particularly in reducing apnea episodes.

Q: Can caffeine citrate replace other treatments?

No, it is specifically indicated for apnea of prematurity and not a substitute for other therapies.

Also known as: Caffeine citrate, Cyclic AMP booster, Caffeine succinate, Caffeine Citrate

Overview

Caffeine citrate is a pharmaceutical formulation that combines caffeine with citric acid, enhancing its solubility and bioavailability. This compound is primarily utilized in clinical settings, especially for the treatment of apnea of prematurity (AOP) in preterm infants. It allows for both intravenous and oral administration, making it versatile for neonatal care. Caffeine, a natural stimulant sourced from coffee beans and tea leaves, presents a favorable safety profile in its citrate form compared to traditional methylxanthines, such as aminophylline. Extensive research demonstrates caffeine citrate's effectiveness in reducing apnea episodes and improving respiratory function in vulnerable infants, making it a preferred option in neonatal intensive care units.

Benefits

Caffeine citrate is proven to significantly reduce apnea episodes among preterm infants with AOP, showing comparable efficacy to aminophylline in the initial treatment phase (odds ratio 1.05, 95% CI: 0.40-2.74, P = 0.914). Furthermore, it is associated with a lower incidence of adverse effects, specifically tachycardia (odds ratio 0.22, 95% CI: 0.13-0.37, P < 0.001) and feeding intolerance (odds ratio 0.40, 95% CI: 0.23-0.70, P = 0.001). This results in fewer overall adverse events, promoting a safer therapeutic profile for this delicate population (odds ratio 0.41, 95% CI: 0.17-0.97, P = 0.042).

How it works

Caffeine citrate functions primarily as an antagonist of adenosine receptors, particularly A1 and A2A subtypes in the central nervous system. By blocking these receptors, caffeine citrate enhances alertness and stimulates increased respiratory activity, crucial for alleviating apnea episodes in preterm infants. This heightened respiratory drive stabilizes both heart rate and respiratory function, addressing key physiological challenges faced by these vulnerable infants.

Side effects

While caffeine citrate is generally associated with a lower incidence of adverse effects compared to other methylxanthines, it may still lead to side effects such as tachycardia and hyperglycemia, which can occur in over 5% of patients. Severe reactions typically seen with methylxanthines are rare when monitoring is adequate. However, caution is advisable concerning drug interactions, particularly with stimulants like theophylline. Contraindications include severe heart disease and hypertension, emphasizing the need for precise dosing and careful monitoring to ensure safe administration in preterm infants.

Dosage

The standard initial dose of caffeine citrate for preterm infants is a loading dose of 20 mg/kg, followed by maintenance doses ranging from 5 to 10 mg/kg every 24 hours. This dosing schedule may be adjusted based on clinical response and the infant's condition. Caffeine citrate exhibits high bioavailability and can be administered both orally and intravenously. Although specific upper limits for safety have not been determined, ongoing monitoring and clinical management are crucial to ensure appropriate dosing and safety.